keyword
MENU ▼
Read by QxMD icon Read
search

prolactin antipsychotic

keyword
https://www.readbyqxmd.com/read/28199787/prolactin-elevating-antipsychotics-and-the-risk-of-endometrial-cancer
#1
Adi J Klil-Drori, Hui Yin, Haim A Abenhaim, Guillaume Galbaud du Fort, Laurent Azoulay
BACKGROUND: The use of antipsychotics may increase the risk of endometrial cancer through elevation of prolactin levels. We investigated the association between antipsychotics that are known to cause prolactin elevation and the risk of endometrial cancer. METHODS: In data from the United Kingdom Clinical Practice Research Datalink, all women who were newly treated with antipsychotics from 1990-2013 were identified and followed until 2014. Within this cohort of antipsychotic users, a nested case-control analysis was conducted...
February 14, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28129701/how-gender-affects-the-pharmacotherapeutic-approach-to-treating-psychosis-a-systematic-review
#2
Bettina Lange, Juliane Katrina Mueller, F Markus Leweke, Jan Malte Bumb
The effectiveness, effective dosages and side effect profiles of antipsychotic medication differ significantly between the sexes. Areas covered: We present a systematic review of gender-differences in the treatment of psychosis focusing on randomized, controlled trials and meta-analyses. Expert opinion: Despite many years of research, the database on gender-differences affecting the pharmacotherapeutic approach to treating psychosis is insufficient. Currently, the US National Institute of Health encouraged the enrolment of female participants in federally supported phase III clinical trials to increase the data available of female patients...
January 27, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28127934/antipsychotic-augmentation-vs-monotherapy-in-schizophrenia-systematic-review-meta-analysis-and-meta-regression-analysis
#3
Britta Galling, Alexandra Roldán, Katsuhiko Hagi, Liz Rietschel, Frozan Walyzada, Wei Zheng, Xiao-Lan Cao, Yu-Tao Xiang, Mathias Zink, John M Kane, Jimmi Nielsen, Stefan Leucht, Christoph U Correll
Antipsychotic polypharmacy in schizophrenia is much debated, since it is common and costly with unclear evidence for its efficacy and safety. We conducted a systematic literature search and a random effects meta-analysis of randomized trials comparing augmentation with a second antipsychotic vs. continued antipsychotic monotherapy in schizophrenia. Co-primary outcomes were total symptom reduction and study-defined response. Antipsychotic augmentation was superior to monotherapy regarding total symptom reduction (16 studies, N=694, standardized mean difference, SMD=-0...
February 2017: World Psychiatry: Official Journal of the World Psychiatric Association (WPA)
https://www.readbyqxmd.com/read/28108225/female-schizophrenia-patients-and-risk-of-breast-cancer-a-population-based-cohort-study
#4
Ana Isabel Wu Chou, Yu-Chiao Wang, Cheng-Li Lin, Chia-Hung Kao
OBJECTIVE: Breast cancer is the most common type of cancer in women. This population-based cohort study aimed to examine the association between breast cancer in female schizophrenia patients and its association with the use of antipsychotics drugs. METHODS: All study subjects were selected from the Taiwan Insurance Claims Data (1998-2008). We compared the risk for breast cancer between female schizophrenia patients receiving antipsychotics (n=29,641) with female patients without any serious mental illnesses nor receiving antipsychotic drugs (n=59,282)...
January 17, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28008301/iloperidone-in-the-treatment-of-schizophrenia-an-evidence-based-review-of-its-place-in-therapy
#5
REVIEW
Fernanda S Tonin, Astrid Wiens, Fernando Fernandez-Llimos, Roberto Pontarolo
INTRODUCTION: Schizophrenia is a chronic and debilitating mental disorder that affects the patient's and their family's quality of life, as well as financial costs and health care settings. Despite the variety of available antipsychotics, optimal treatment outcomes are not always achieved. Novel drugs, such as iloperidone, can provide more effective, tolerable and safer strategies. AIM: To review the evidence for the clinical impact of iloperidone on the treatment of patients with schizophrenia...
2016: Core Evidence
https://www.readbyqxmd.com/read/27932884/a-randomized-trial-of-aripiprazole-vs-blonanserin-for-the-treatment-of-acute-schizophrenia-and-related-disorders
#6
Taro Kishi, Yuki Matsuda, Shinji Matsunaga, Tomohiko Mukai, Masatsugu Moriwaki, Hideaki Tabuse, Kiyoshi Fujita, Nakao Iwata
OBJECTIVE: There has been no direct comparison of aripiprazole and blonanserin for schizophrenia treatment. We conducted a 24-week, rater-masked, randomized trial of aripiprazole (6-30 mg/d) vs blonanserin (4-24 mg/d) in schizophrenia patients who were not taking any antipsychotic medication for more than 2 weeks before enrollment (UMIN000011194). METHODS: The primary outcome measure for efficacy was improvement of Positive and Negative Syndrome Scale (PANSS) total score at week 24...
2016: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/27866695/does-formulation-matter-a-systematic-review-and-meta-analysis-of-oral-versus-long-acting-antipsychotic-studies
#7
REVIEW
Giovanni Ostuzzi, Irene Bighelli, Ryuhei So, Toshi A Furukawa, Corrado Barbui
Recently, many authors highlighted the potential advantages of a broader prescription of long-acting injectable antipsychotics (LAIs) based on various assumptions, including favorable pharmacokinetic features. In this systematic review, data from randomized controlled trials comparing LAIs versus the oral formulation of the same antipsychotic were meta-analyzed in order to ascertain whether the route of administration may be associated with a different efficacy and tolerability profile. Of 21 included studies, 18 contributed to the meta-analysis, providing data for risperidone, olanzapine, aripiprazole, zuclopenthixol, fluphenazine and haloperidol...
November 17, 2016: Schizophrenia Research
https://www.readbyqxmd.com/read/27825323/prolactin-related-adverse-events-and-change-in-prolactin-levels-in-pediatric-patients-given-antipsychotics-for-schizophrenia-and-schizophrenia-spectrum-disorders-a-systematic-review
#8
Eric Druyts, Michael J Zoratti, Kabirraaj Toor, Ping Wu, Salmaan Kanji, Kiran Rabheru, Edward J Mills, Kristian Thorlund
BACKGROUND: Second-generation antipsychotics are commonly prescribed for pediatric patients with schizophrenia and schizophrenia spectrum disorders despite their lack of approval for use in children. Although considered a safer alternative to first-generation antipsychotics, there is evidence to suggest that second-generation antipsychotics may be associated with some adverse events as well as an increase in prolactin levels. The purpose of this review is to examine the risk of prolactin-related adverse events in pediatric patients using antipsychotics and to quantify changes in prolactin for this population...
November 9, 2016: BMC Pediatrics
https://www.readbyqxmd.com/read/27823949/risk-of-breast-cancer-in-risperidone-users-a-nationwide-cohort-study
#9
Johan Reutfors, Louise Wingård, Lena Brandt, Yiting Wang, Hong Qiu, Helle Kieler, Shahram Bahmanyar
BACKGROUND: Several antipsychotics, especially risperidone, are known to increase serum prolactin. Hyperprolactinemia has been linked to the development of mammary gland tumors in animal studies. We therefore investigated the risk of breast cancer in a nationwide cohort of women using risperidone or other antipsychotics. METHODS: All women, 18years or older, who initiated treatment with risperidone or any other antipsychotic between 2006 and 2012 were identified in Swedish nationwide registers...
November 4, 2016: Schizophrenia Research
https://www.readbyqxmd.com/read/27807604/safety-and-tolerability-of-cariprazine-in-the-long-term-treatment-of-schizophrenia-results-from-a-48-week-single-arm-open-label-extension-study
#10
Suresh Durgam, William M Greenberg, Dayong Li, Kaifeng Lu, Istvan Laszlovszky, Gyorgy Nemeth, Raffaele Migliore, Stephen Volk
RATIONALE: Cariprazine, a dopamine D3/D2 receptor partial agonist antipsychotic, demonstrated efficacy and tolerability in 6-week, randomized, placebo-controlled schizophrenia trials. Schizophrenia is a chronic disorder that requires continuous treatment; therefore, the long-term safety and tolerability profile of antipsychotic agents is an important factor in guiding clinician decisions. OBJECTIVE: This single-arm, open-label extension study evaluated the long-term safety and tolerability of cariprazine in patients with schizophrenia...
January 2017: Psychopharmacology
https://www.readbyqxmd.com/read/27800283/prolactin-levels-after-switching-to-paliperidone-palmitate-in-patients-with-schizophrenia
#11
Masaru Nakamura, Takahiko Nagamine, Goro Sato, Kazue Besho
Objective: The aim of this study was to investigate the tolerability and efficacy of paliperidone palmitate and its effect on the levels of prolactin in patients with schizophrenia. Method: A prospective study was carried out in 22 Japanese middle-aged patients with schizophrenia who were switched from paliperidone-extended release or risperidone long-acting injectable to paliperidone palmitate for a minimum of 12 months. Psychotic symptoms using the 18-item Brief Psychiatric Rating Scale, extrapyramidal symptoms using 9-item Drug-induced Extrapyramidal Symptoms Scale, and plasma prolactin levels using fasting blood samples were assessed at Baseline, and one, three, six, and 12 months...
May 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27776952/prolactin-gene-polymorphism-1149-g-t-is-associated-with-hyperprolactinemia-in-patients-with-schizophrenia-treated-with-antipsychotics
#12
Svetlana A Ivanova, Diana Z Osmanova, Anastasia S Boiko, Ivan V Pozhidaev, Maxim B Freidin, Olga Yu Fedorenko, Arkadiy V Semke, Nikolay A Bokhan, Elena G Kornetova, Lubov D Rakhmazova, Bob Wilffert, Anton J M Loonen
BACKGROUND: Antipsychotic drugs can cause hyperprolactinemia. However, hyperprolactinemia was also observed in treatment-naive patients with a first schizophrenic episode. This phenomenon might be related to the role of prolactin as a cytokine in autoimmune diseases. Extrapituitary prolactin production is regulated by an alternative promoter, which contains the functional single nucleotide polymorphism -1149 G/T (rs1341239). We examined whether this polymorphism was associated with hyperprolactinemia in patients with schizophrenia...
October 21, 2016: Schizophrenia Research
https://www.readbyqxmd.com/read/27755159/peony-glycyrrhiza-decoction-for-antipsychotic-related-hyperprolactinemia-in-women-with-schizophrenia-a-randomized-controlled-trial
#13
Sui Cheung Man, Xian-Bin Li, Huai-Hai Wang, Hai-Ning Yuan, Hua-Ning Wang, Rui-Guo Zhang, Qing-Rong Tan, Hei Kiu Wong, Grainne M McAlonan, Chuan-Yue Wang, Zhang-Jin Zhang
OBJECTIVES: An herbal preparation called peony-glycyrrhiza decoction (PGD) may have the potential in reducing antipsychotic-related hyperprolactinemia (hyperPRL). This double-blind, randomized placebo-controlled study aimed to reevaluate the efficacy of PGD against antipsychotic-related hyperPRL. METHODS: Ninety-nine schizophrenic women who were under antipsychotic therapy and had symptomatic hyperPRL were randomly assigned to additional treatment with placebo (n = 50) or PGD (n = 49, 45 g/d) for 16 weeks...
December 2016: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27732772/the-use-of-long-acting-injectable-antipsychotics-in-schizophrenia-evaluating-the-evidence
#14
Christoph U Correll, Leslie Citrome, Peter M Haddad, John Lauriello, Mark Olfson, Stephen M Calloway, John M Kane
Long-acting injectable antipsychotics (LAIs) are among the most effective treatments in psychiatry, yet they remain underutilized in clinical practice. Although LAIs are typically used to maintain treatment adherence in patients with chronic schizophrenia, recent research has suggested that they may also provide an effective treatment strategy for patients with early-phase or first-episode disease. In October 2015, a group of 8 experts on the management of schizophrenia and LAIs met to evaluate the evidence surrounding the efficacy, safety, and cost-effectiveness of LAIs and to develop practical recommendations regarding the clinical use, education, and unmet needs related to LAIs...
2016: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/27672485/brexpiprazole-a-new-treatment-option-for-schizophrenia
#15
REVIEW
Jonathan R Scarff
Schizophrenia occurs in approximately 0.3 to 0.7 percent of the world's population and is associated with significant morbidity and mortality. Although atypical antipsychotics reduce positive and negative symptoms, they are associated with varying degrees of metabolic adverse effects. This necessitates continued development of efficacious yet metabolically favorable treatments. This article reviews brexpiprazole, a medication recently approved to treat patients with schizophrenia. Brexpiprazole was well-tolerated, and adverse reactions were statistically insignificant...
July 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27658834/the-effect-of-antipsychotics-on-bone-mineral-density-and-sex-hormones-in-male-patients-with-schizophrenia
#16
Süheyla Doğan Bulut, Serdar Bulut, Dicle Görkem Atalan, Rıza Gökçer Tulaci, Türker Türker, Eda Gürçay, Çiğdem Aydemir
BACKGROUND: The aim of this study was to compare the bone mineral density (BMD) of male schizophrenia patients with those of healthy controls in order to determine the relationship between BMD and hormonal changes. SUBJECTS AND METHODS: The study sample included male outpatients between 18 and 55 years old, diagnosed with schizophrenia who had used prolactin-raising antipsychotics (n=23) and prolactin-sparing antipsychotics (n=19) for at least twelve months, along with an age - matched healthy control group...
September 2016: Psychiatria Danubina
https://www.readbyqxmd.com/read/27658833/antipsychotic-treatment-prolactin-and-breast-tumorigenesis
#17
Marc De Hert, Davy Vancampfort, Brendon Stubbs, Tine Sabbe, Hans Wildiers, Johan Detraux
BACKGROUND: Over the last decades prolactin (PRL) has gained attention for its possible role in breast tumorigenesis. As all antipsychotics (although differences with respect to PRL elevation are large) have the propensity to induce hyperprolactinemia (HPRL), questions have arisen concerning the influence of PRL-elevating antipsychotic medications on breast cancer risk. SUBJECTS AND METHODS: A literature search (until January 2016), using the MEDLINE database, was conducted for English-language published clinical studies to identify and synthesize data of the current state of knowledge concerning the relationship between HPRL, breast cancer risk (factors) and antipsychotic medication...
September 2016: Psychiatria Danubina
https://www.readbyqxmd.com/read/27639886/-prolactin-antipsychotics-and-breast-cancer-is-there-a-connection
#18
T Sabbe, J Detraux, M De Hert
BACKGROUND: The use of antipsychotics can result in elevated prolactin levels or hyperprolactinemia. An increasing number of studies suggests that prolactin plays a role in mammary carcinogenesis, leading to concerns about a possible relationship between antipsychotics and breast cancer.<br/> AIM: To provide an overview of recent literature regarding the relationship between prolactin, antipsychotics and breast cancer and an association between schizophrenia and breast cancer...
2016: Tijdschrift Voor Psychiatrie
https://www.readbyqxmd.com/read/27629292/once-monthly-paliperidone-palmitate-compared-with-conventional-and-atypical-daily-oral-antipsychotic-treatment-in-patients-with-schizophrenia
#19
Edward Kim, Christoph U Correll, Lian Mao, H Lynn Starr, Larry Alphs
OBJECTIVE: This analysis of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study (NCT01157351) compared outcomes after administration of once-monthly paliperidone palmitate (PP) vs conventional oral antipsychotics (COAs) or atypical oral antipsychotics (AOAs). METHODS: PRIDE was a 15-month study of 444 individuals with schizophrenia and a history of incarceration. They were randomly assigned to PP or to 1 of 7 commonly prescribed OAs...
September 15, 2016: CNS Spectrums
https://www.readbyqxmd.com/read/27574838/effect-of-aripiprazole-lauroxil-on-metabolic-and-endocrine-profiles-and-related-safety-considerations-among-patients-with-acute-schizophrenia
#20
Henry A Nasrallah, John W Newcomer, Robert Risinger, Yangchun Du, Jacqueline Zummo, Anjana Bose, Srdjan Stankovic, Bernard L Silverman, Elliot W Ehrich
OBJECTIVE: Aripiprazole lauroxil, a long-acting injectable antipsychotic, demonstrated safety and efficacy in treating symptoms of schizophrenia in a double-blind, placebo-controlled trial. Because the metabolic profile of antipsychotics is an important safety feature, the effects of aripiprazole lauroxil on body weight, endocrine and metabolic profiles, and safety were examined in a secondary analysis. METHODS: Patients with schizophrenia (DSM-IV-TR criteria) were randomly assigned to aripiprazole lauroxil 441 mg, aripiprazole lauroxil 882 mg, or placebo intramuscularly once monthly between December 2011 and March 2014...
November 2016: Journal of Clinical Psychiatry
keyword
keyword
51269
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"